Literature DB >> 22215853

ALK gene amplified in most inflammatory breast cancers.

Rabiya S Tuma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22215853     DOI： 10.1093/jnci/djr553

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  11 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.

Authors:  Shou-Wei Jia; Sha Fu; Fang Wang; Qiong Shao; Hong-Bing Huang; Jian-Yong Shao
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 3.  Equal access to innovative therapies and precision cancer care.

Authors:  Agnès Buzyn; Jean-Yves Blay; Natalie Hoog-Labouret; Marta Jimenez; Frédérique Nowak; Marie-Cécile Le Deley; David Pérol; Christian Cailliot; Jacques Raynaud; Gilles Vassal
Journal:  Nat Rev Clin Oncol       Date:  2016-03-22       Impact factor: 66.675

4.  Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.

Authors:  Jianyong Chen; Yunlong Zhou; Xuyuan Dong; Liu Liu; Longchuan Bai; Donna McEachern; Sally Przybranowski; Chao-Yie Yang; Jeanne Stuckey; Xiaoqin Li; Bo Wen; Ting Zhao; Siwei Sun; Duxin Sun; Lingling Jiao; Yu Jing; Ming Guo; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2020-11-13       Impact factor: 7.446

5.  Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma.

Authors:  Savitri Krishnamurthy; Wendy Woodward; Wei Yang; James M Reuben; James Tepperberg; Dai Ogura; Shin-Ichiro Niwa; Lei Huo; Yun Gong; Randa El-Zein; Ana M Gonzalez-Angulo; Mariana Chavez-Macgregor; Ricardo Alvarez; Anthony Lucci; Vicente Valero; Naoto T Ueno
Journal:  Springerplus       Date:  2013-08-28

6.  ALK gene amplification is associated with poor prognosis in colorectal carcinoma.

Authors:  P Bavi; Z Jehan; R Bu; S Prabhakaran; N Al-Sanea; F Al-Dayel; M Al-Assiri; T Al-Halouly; R Sairafi; S Uddin; K S Al-Kuraya
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

7.  Genetics of Bladder Malignant Tumors in Childhood.

Authors:  Andrea Zangari; Johan Zaini; Caterina Gulìa
Journal:  Curr Genomics       Date:  2016-02       Impact factor: 2.236

8.  A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor.

Authors:  Xun Bao; Jianmei Wu; Nader Sanai; Jing Li
Journal:  J Pharm Anal       Date:  2017-07-14

9.  ALK alteration is a frequent event in aggressive breast cancers.

Authors:  Abdul K Siraj; Shaham Beg; Zeenath Jehan; Sarita Prabhakaran; Maqbool Ahmed; Azhar R Hussain; Fouad Al-Dayel; Asma Tulbah; Dahish Ajarim; Khawla S Al-Kuraya
Journal:  Breast Cancer Res       Date:  2015-09-17       Impact factor: 6.466

Review 10.  ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.

Authors:  Mingxiang Ye; Xinxin Zhang; Nan Li; Yong Zhang; Pengyu Jing; Ning Chang; Jianxiong Wu; Xinling Ren; Jian Zhang
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.